<DOC>
	<DOCNO>NCT00025480</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth tumor cell block enzymes need cell growth make tumor cell sensitive radiation therapy . Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell either kill cell stop dividing may also make tumor cell sensitive radiation therapy . PURPOSE : This phase I trial study side effect best dose tipifarnib give together radiation therapy combination chemotherapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Tipifarnib Plus Radiation Therapy After Combination Chemotherapy Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity tipifarnib give concurrently radiotherapy induction chemotherapy comprise paclitaxel carboplatin follow maintenance therapy tipifarnib patient stage IIIA IIIB non-small cell lung cancer . - Determine tumor response 3 month patient treat regimen . OUTLINE : This multicenter , dose-escalation study tipifarnib . Patients receive induction chemotherapy comprise carboplatin IV 30 minute day 1 paclitaxel IV 1 hour day 1 , 8 , 15 . Treatment repeat every 28 day 2 course . Beginning 4-6 week completion induction chemotherapy , patient receive oral tipifarnib twice daily 7 week . Patients undergo radiotherapy daily 5 day week 7 week begin 3 day start tipifarnib . After completion radiotherapy , patient receive oral tipifarnib twice daily 4 day daily 4 day . Cohorts 3-6 patient receive escalate dos tipifarnib receive radiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Beginning 4-6 week completion radiotherapy tipifarnib , patient receive maintenance therapy comprise oral tipifarnib twice daily day 1-21 . Maintenance therapy repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 3 , 6 , 12 month . PROJECTED ACCRUAL : Approximately 9-12 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Locally advance ( stage IIIA IIIB ) disease require radiotherapy No malignant pleural effusion PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL No grade 2 great elevation liver function test Renal : Creatinine great 1.5 time normal Pulmonary : FEV_1 least 600 cc Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No grade 3 4 peripheral neuropathy No known allergy imidazole drug ( e.g. , ketoconazole , miconazole , econazole , terconazole ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Up 2 prior concurrent carboplatin paclitaxel chemotherapy regimens allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior thoracic radiotherapy Surgery : At least 3 week since prior exploratory thoracotomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>